| アブストラクト | BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, recurrent condition that presents as painful, suppurating lesions in the apocrine gland-bearing skin regions. HS has been associated with increased suicidal behaviours (SB), independent of any treatment. TNF-alpha antagonists are used to treat moderate-to-severe HS and have also been associated with SB, a factor that could confound the decision to use the TNF-alpha antagonists in the moderately to severely affected HS patients, who may already be experiencing increased SB risk. OBJECTIVES: To determine presence or absence of a safety signal for SB when HS is treated with TNF-alpha antagonists. METHODS: We calculated the reporting odds ratios (ROR) with 95% CI of SB associated with treatment for HS with TNF-alpha antagonists vs. the reference group of all other treatments for HS in the US Food and Drug Administration pharmacovigilance database from 1 January 2004 to 31 March 2019. A second analysis excluded isotretinoin (which has been used to treat HS and has also been associated with SB) from the reference group. RESULTS: There was a signal for decreased risk of SB with TNF-alpha antagonists (ROR = 0.1959, 95% CI 0.1247-0.3079; z = 7.071, P < 0.0001] vs. all other HS treatments; the ROR did not change significantly after isotretinoin was excluded from the reference group. CONCLUSIONS: Treatment of HS with TNF-alpha antagonists is associated with a decreased risk of SB. |
|---|
| ジャーナル名 | Journal of the European Academy of Dermatology and Venereology : JEADV |
|---|
| Pubmed追加日 | 2020/1/26 |
|---|
| 投稿者 | Gupta, M A; Vujcic, B; Sheridan, A D; Gupta, A K |
|---|
| 組織名 | Department of Psychiatry, Schulich School of Medicine and Dentistry, University;of Western Ontario, London, ON, Canada.;Department of Medicine, University of Toronto Faculty of Medicine, Toronto, ON,;Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31981260/ |
|---|
